Zheng Quan Ri Bao·2025-05-18 15:55Core Viewpoint - The successful nomination of independent director Du Jian by the China Securities Investor Services Center marks a significant step in the reform of the independent director system in China, following the first case with First Pharmaceutical in June 2024, indicating a trend towards improved corporate governance in listed companies [1][4]. Group 1: Nomination Process - The nomination of Du Jian was conducted in collaboration with institutional investors, adhering to market-oriented and legal principles, and received support from 8 shareholders, representing approximately 1.2288% of the total voting rights of Shangfeng Cement [2]. - The voting results showed that the shares in favor of the nomination exceeded the required threshold, indicating that the center could potentially nominate candidates independently in the future [2][3]. Group 2: Impact on Corporate Governance - The initiative by the China Securities Investor Services Center to publicly nominate independent directors has garnered widespread attention and is seen as a positive exploration for enhancing internal governance of listed companies [4]. - The involvement of the center allows for a more rigorous selection of independent directors based on their past performance and ability to protect minority shareholders' rights, thereby improving the overall governance of listed companies [4][5]. - The successful implementation of this nomination process is expected to encourage more investors to exercise their shareholder rights, thereby enhancing the supervisory and balancing forces within corporate governance structures [5].